FDA Clearance Tracker · P150025-S018
PD-L1 IHC 28-8 pharmDx
Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jul 1, 2026
Approved
Time to decision
180 days
Received Jan 2, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P150025-S018
- Device name
- PD-L1 IHC 28-8 pharmDx
- Applicant
- Agilent Technologies, Inc.
- Applicant location
- Santa Clara, CA
- Received
- Jan 2, 2026
- Decided
- Jul 1, 2026
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P150025
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the PD-L1 IHC 28-8 pharmDx for expanding the indications to include use as an aid in identifying patients with esophageal squamous cell carcinoma (ESCC), and gastric, gastroesophageal junction (GEJ) and esophageal adenocarcinoma for treatment with OPDIVO (nivolumab) or OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy).
Source documents
Other decisions for Agilent Technologies, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PD-L1 IHC 22C3 pharmDxPMA supplement
P150013-S032 · Decided Feb 11, 2026 · 187 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.